{"id":"089c21c1ceb9","type":"article","url":"https://hartvaat.nl/2020/07/28/evolocumab-op-atherogene-lipoproteinen-in-de-peri-infarctperiode-gerandomiseerde/","title":"Evolocumab op atherogene lipoproteïnen in de peri-infarctperiode: gerandomiseerde trial","title_en":"Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["lipoproteïne-a","yellow-iii"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.046320","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.046320","authors":["Thorsten M Leucker","Michael J Blaha","Steven R Jones","Michael A Vavuranakis","Marlene S Williams","Hong Lai","Thomas H Schindler","Jacqueline Latina","Steven P Schulman","Gary Gerstenblith"],"significance":7,"published":"2020-07-28","source_date":"2020-07-28","image":"","kennis":[],"congress":"","summary_en":"This placebo-controlled trial of evolocumab in the peri- and early post-infarction period demonstrated rapid and substantial reductions in atherogenic lipoproteins when initiated acutely during MI hospitalization.","created":"2026-07-03T10:28:41Z","updated":"2026-07-03T13:27:50Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde placebogecontroleerde trial van evolocumab op atherogene lipoproteïnen in de acute en vroege post-infarctperiode.","abstract_original":""}